PP405 is a promising new treatment for hairloss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
A user is struggling with hairloss at 17 and has been using finasteride for 5 months and minoxidil for 11 months without seeing regrowth. Other users encourage continuing treatment, sharing their own experiences with finasteride, minoxidil, and dermarolling, and emphasizing patience and acceptance.
The user shared their positive experience with finasteride for hairloss over seven years, noting it stopped hair recession and maintained their hairline. They also mentioned using minoxidil irregularly and experiencing a lower sperm count but no erectile dysfunction.
The conversation is about using finasteride and testosterone replacement therapy (TRT) for hairloss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.